Shanghai Shyndec Pharmaceutical (SHA:600420) received a drug registration certificate from China's National Medical Products Administration for ibrutinib capsules, according to a Shanghai bourse filing on Friday.
The drug is used to treat cancers such as lymphoma and Waldenström Macroglobulinemia.
The pharmaceutical company invested 15.6 million yuan into the drug's research and development.